Glaxosmithkline Pharmaceuticals is currently trading at Rs 2427.20, down by 53.80 points or 2.17 % from its previous closing of Rs 2481.00 on the BSE.
The scrip opened at Rs 2472.00 and has touched a high and low of Rs 2493.95 and Rs. 2425.65 respectively. So far 705 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 10 has touched a 52 week high of Rs 2899.00 on 03-Jun-2013 and a 52 week low of Rs 1950.00 on 19-Nov-2012.
Last one week high and low of the scrip stood at Rs 2511.00 and Rs 2431.10 respectively. The current market cap of the company is Rs 20972.47 crore.
The promoters holding in the company stood at 50.67% while Institutions and Non-Institutions held 34.37% and 14.96% respectively.
GlaxoSmithKline Pharmaceuticals has reported results for third quarter ended September 30, 2013.
The company has reported a fall of 33.73% in its net profit at Rs 100.95 crore for the quarter as compared to Rs 152.34 crore for the same quarter in the previous year. Total income of the company has decreased by 7.03% at Rs 666.02 crore for quarter under review as compared to Rs 716.37 crore for the quarter ended September 30, 2012.
GlaxoSmithKline Pharmaceuticals is one oldest pharmaceutical company in India. Internationally it has created many brands such as Ribena, Horlicks, Lucozade, Aquafresh, Sensodyne, Panadol, Tums and Zovirax, among others. It employs 5,000 people and has turnover of more than $1 billion in India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: